Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.38 |
| ▸ | ITK | Q08881 | 7/20 | 0.37 |
| ▸ | EGFR | P00533 | 8/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623071 | 0.96 | SYK (0.46) | SYKP2RX3ITKEGFRAURKB | |
| SCHEMBL4340593 | 0.92 | STK17B (0.41) | SYKP2RX3EGFRAURKBSTK17B | |
| SCHEMBL1024947 | 0.92 | P2RX3 (0.37) | SYKP2RX3ITKEGFRAURKB | |
| SCHEMBL4341114 | 0.91 | SYK (0.50) | SYKP2RX3ITKEGFR | |
| SCHEMBL13623074 | 0.89 | P2RX3 (0.38) | SYKP2RX3ITKEGFRAURKB | |
| SCHEMBL1027538 | 0.88 | SYK (0.41) | SYKP2RX3ITKEGFRAURKB | |
| SCHEMBL13622748 | 0.88 | STK17B (0.43) | SYKP2RX3EGFRAURKBSTK17B | |
| SCHEMBL13623076 | 0.86 | SYK (0.54) | SYKP2RX3ITKEGFRCDK1 | |
| SCHEMBL13623063 | 0.84 | SYK (0.55) | SYKITKEGFRCDK1 | |
| SCHEMBL2523055 | 0.83 | STK17B (0.44) | P2RX3ITKEGFRSTK17BSTK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | SYK 46/4885P2RX3 3525/4885ITK 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.